News
CG Oncology’s lead investigational drug, cretostimogene grenadenorepvec, an oncolytic immunotherapy, showed promising results in clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback